MOR103 Presentation - MorphoSys
MOR103 Presentation - MorphoSys
MOR103 Presentation - MorphoSys
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Conclusions<br />
• <strong>MOR103</strong> showed favorable safety data in all active<br />
treatment groups<br />
• <strong>MOR103</strong> showed promising therapeutic activity<br />
• Consistent responses seen in clinical parameters<br />
• Rapid onset of therapeutic effect within 2 weeks<br />
• Sustained response up to 10 weeks beyond treatment<br />
• The 1.0 mg/kg group demonstrates the efficacy<br />
potential of <strong>MOR103</strong><br />
• Imaging supports anti-inflammatory activity of<br />
<strong>MOR103</strong><br />
ACR/ARHP 2012 – Washington DC – November 10-14, 2012
Change language